PROCEPT BioRobotics (NASDAQ:PRCT) EVP Sells $163,340.40 in Stock

Key Points

• EVP Alaleh Nouri sold 6,892 shares of PROCEPT on March 6 at an average price of $23.70 for proceeds of $163,340.40, trimming her position by 5.69% to 114,264 shares (≈$2.71M).
• PROCEPT missed quarterly expectations, reporting EPS of ($0.53) vs. ($0.32) consensus and revenue of $76.38M vs. $93.7M expected, leaving a negative net margin of 31.02% despite 11.9% year‑over‑year revenue growth.
• Shares trade near $25.26 with a market cap of about $1.42B and 50/200‑day averages of $29.25/$32.93; analysts are mixed but the consensus rating is a Hold with an average price target of $40.82.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) EVP Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $163,340.40. Following the sale, the executive vice president directly owned 114,264 shares of the company's stock, valued at $2,708,056.80. The trade was a 5.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock traded up $1.04 on Monday, hitting $25.26. The stock had a trading volume of 2,163,428 shares, compared to its average volume of 1,640,943. The business's 50 day moving average is $29.25 and its two-hundred day moving average is $32.93. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. PROCEPT BioRobotics Corporation has a twelve month low of $19.35 and a twelve month high of $66.85. The company has a quick ratio of 5.77, a current ratio of 6.85 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.21). The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.35) EPS. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently modified their holdings of PRCT. Caitong International Asset Management Co. Ltd boosted its holdings in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock valued at $29,000 after acquiring an additional 746 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of PROCEPT BioRobotics during the third quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at about $40,000. Vega Investment Solutions grew its holdings in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company's stock worth $45,000 after purchasing an additional 265 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company's stock worth $60,000 after purchasing an additional 1,079 shares during the last quarter. Institutional investors own 89.46% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Robert W. Baird began coverage on PROCEPT BioRobotics in a research note on Friday. They issued a "neutral" rating and a $30.00 price target on the stock. TD Cowen lowered their price target on PROCEPT BioRobotics from $50.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Wall Street Zen downgraded PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research report on Saturday, February 28th. Finally, Jefferies Financial Group lowered PROCEPT BioRobotics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of "Hold" and an average price target of $40.82.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.